Clinical trials: Vascular Conditions
Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.
- Trial name
- GLOW2 (NCT06270836)
- Testing
- Tarcocimab
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 255 people
- Sponsor
- Kodiak Sciences Inc
Relapsed and Refractory Multiple Myeloma
BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma
This clinical study is an exploratory study, mainly to study the safety and efficacy of BCMA nano-antibody CAR-T in the treatment of MM. In this study, a 3 + 3 dose gradient climbing design was used.
- Trial name
- BCMA CAR-T (NCT03661554)
- Testing
- BCMA CAR-T Cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Pregene (ShenZhen) Biotechnology Company, Ltd.
Chronic Inducible Urticaria
Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria
This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and cold urticaria.
- Trial name
- CALM-CIndU (NCT06050928)
- Testing
- Oral EP262
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 33 people
- Sponsor
- Escient Pharmaceuticals, Inc
Diabetic Foot Ulcer, Infection
Topical PluroGel PN for the Treatment of Mildly Infected Diabetic Foot Ulcers
This is an open label study of subjects who have failed Protocol PGN-1300. Adult subjects (greater than 18 years old) who present with a mildly infected diabetic foot ulcer (IDSA criteria) having full thickness (i.e., through the…
- Trial name
- NCT02119754
- Testing
- Plurogel PN
- Where
- 15 sites in United States
- Volunteers
- 15 people
- Sponsor
- PluroGen Therapeutics, Inc
Kidney Transplantation
Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients
The purpose of this study is evaluate the safety and tolerability of Diannexin in kidney transplant recipients.
- Trial name
- NCT00615966
- Testing
- Diannexin
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- Alavita Pharmaceuticals Inc
Hypertension
Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine and Losartan in Health Volunteers
The purpose of this study is to evaluate the comparative bioavailability of two fixed dose combination tablet formulations of amlodipine and losartan in healthy volunteers.
- Trial name
- NCT01648231
- Testing
- Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state, Fixed Dose Combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state, Fixed Dose Combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
- Where
- Australia
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Stroke, Stroke, Acute
The Safety and Effectiveness of CVA-FLOW Software Device for Acute Ischemic Stroke
The purpose of this study is to demonstrate the effectiveness and safety of CVA-FLOW, a digital health AI based Telestroke system developed by CVAID Ltd.
- Conditions
- Stroke, Stroke, Acute, Stroke, Ischemic, Stroke, Cardiovascular
- Trial name
- NCT05745051
- Testing
- CVAid Flow
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Cvaid Medical
Arterial Occlusive Disease, Intermittent Claudication
Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries
To obtain additional data on safety and efficacy of the Express stent implantation in the treatment of stenosed or occlusive atherosclerotic disease (de novo or restenotic lesions) in the iliac arteries (common or external).
- Conditions
- Arterial Occlusive Disease, Intermittent Claudication, Atherosclerotic Disease, Thrombosis
- Trial name
- MELODIE (NCT00352222)
- Testing
- stent implantation
- Where
- 10 sites in Belgium, Canada and 3 more
- Volunteers
- 150 people
- Sponsor
- Boston Scientific Corporation
Critical Illness, Acute Kidney Injury
Collective Accuryn Physiologic Signals and Signatures
The CAPSS Study is a retrospective and prospective, multi-center, single-arm post-market data collection study with an FDA cleared device.
- Conditions
- Critical Illness, Acute Kidney Injury, Sepsis, Septic Shock
- Trial name
- CAPSS (NCT03817281)
- Testing
- Accuryn Monitoring System
- Where
- United States
- Sponsor
- Potrero Medical
Chronic Idiopathic Urticaria
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
The study is a Phase II, dose-ranging, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of a single subcutaneously administered omalizumab dose as add-on therapy for the…
- Trial name
- NCT00866788
- Testing
- omalizumab, H1 antihistamines, Diphenhydramine
- Volunteers
- 90 people
- Sponsor
- Genentech, Inc.
Peripheral Arterial Disease, Critical Limb Ischemia
ACPs in Severe PAD/CLI by Direct Intramuscular Injection
Study title: A Study of Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients with Critical Limb Ischemia ( ACPs-CLI ) Principle Investigator: Assoc.Prof. Pramook Mutirangura,M.D.
- Trial name
- NCT00523731
- Testing
- Angiogenic Cell Precursors (ACPs) or Vescell TM
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- TheraVitae Ltd.
Intermittent Claudication
Clinical Trial for GNX80 in Intermittent Claudication
This is a Phase 4, randomized clinical trial to evaluate whether GNX80 vs. placebo, prescribed for 6 months to patients with Intermittent Claudication(IC) would lead to an improvement in the walking distance.
- Trial name
- NCT05400395
- Testing
- GNX80
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- SK Chemicals Co., Ltd.
Multiple Myeloma, Multiple Myeloma in Relapse
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
This is a phase I/II study of perifosine in combination with bortezomib-with or without dexamethasone-for patients with relapsed or refractory multiple myeloma previously treated with bortezomib.
- Trial name
- NCT00401011
- Testing
- Perifosine, Bortezomib, Dexamethasone
- Volunteers
- 84 people
- Sponsor
- AEterna Zentaris
Diabetic Foot Ulcer, Venous Leg Ulcer
Real World Evidence with the Debritom+ TM Novel Micro Water Jet Technology At a Single Wound Center
Prospective, single-blinded, single-center, parallel group, randomized controlled trial (RCT) to assess rate and frequency of wound healing and associated financial savings, when using Medaxis debritom+ versus standard of care as…
- Conditions
- Diabetic Foot Ulcer, Venous Leg Ulcer, Surgical Wound Dehiscence, Traumatic Wounds
- Trial name
- EVIDENT (NCT04920253)
- Testing
- Study Device Debridement, SOC Debridement
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Medaxis, LLC
Subarachnoid Hemorrhage
Intravenous Nitrite Infusion for Reversal of Cerebral Vasospasm After Subarachnoid Hemorrhage
The hypothesis is that intravenous infusion of sodium nitrite is safe and effective for the reversal of cerebral vasospasm after subarachnoid hemorrhage in patients with a cerebral aneurysm.
- Trial name
- NCT02176837
- Testing
- Sodium Nitrite
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Hope Pharmaceuticals
Tetraplegia/Tetraparesis, Quadriplegia
GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
The GB-PRIME Study is an early feasibility study designed to assess the clinical safety and functionality of the Neuralink N1 Implant and R1 Robot.
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury
- Trial name
- GB-PRIME (NCT07127172)
- Testing
- N1 Implant, R1 Robot
- Where
- 2 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Neuralink Corp
Intermittent Claudication
Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication
The purpose of this study is to evaluate the safety and pharmacokinetics of multiple, once-daily, intravenous doses of trans sodium crocetinate (TSC).
- Trial name
- NCT00725881
- Testing
- Trans sodium crocetinate (TSC), 0.9% normal saline
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Diffusion Pharmaceuticals Inc
Myocardial Infarction
Safety and Efficacy Study of MGuard Stent After a Heart Attack
The goal of this study is to demonstrate the superiority of the MGuard™ stent over commercially-approved bare-metal (BMS) /drug-eluting stents (DES) in achieving better myocardial reperfusion in primary angioplasty for the…
- Trial name
- MASTER (NCT01368471)
- Testing
- MGuard, Control BMS or DES
- Where
- 7 sites in Poland, South Africa
- Volunteers
- 433 people, healthy volunteers welcome
- Sponsor
- InspireMD
Post-Stroke Spasticity, Cerebrovascular Accident
Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity
This is a study to confirm the superior efficacy of a single treatment of GSK1358820 over placebo in patients with post-stroke upper limb spasticity of both the wrist and finger flexors using the Modified Ashworth Scale (MAS)…
- Trial name
- NCT00460564
- Testing
- GSK1358820
- Where
- 18 sites in Japan
- Volunteers
- 109 people
- Sponsor
- GlaxoSmithKline
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.